Topics:

Yaupon locks up phase II Clearazide trial

Yaupon locks up phase II Clearazide trial

Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.

The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.